Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Corient Private Wealth LLC

Corient Private Wealth LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 86.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,380 shares of the company's stock after buying an additional 1,101 shares during the quarter. Corient Private Wealth LLC's holdings in Medpace were worth $791,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in MEDP. Proficio Capital Partners LLC grew its stake in Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company's stock valued at $80,575,000 after acquiring an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Medpace in the fourth quarter valued at about $78,144,000. Iron Triangle Partners LP purchased a new stake in shares of Medpace during the third quarter worth about $64,371,000. GW&K Investment Management LLC raised its position in shares of Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after purchasing an additional 133,379 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in Medpace by 36.0% during the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock worth $138,612,000 after buying an additional 109,886 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of recent research reports. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $376.30.

Remove Ads

Medpace Stock Down 2.5 %

NASDAQ:MEDP traded down $7.67 during trading hours on Monday, reaching $304.69. 602,622 shares of the stock were exchanged, compared to its average volume of 299,947. Medpace Holdings, Inc. has a twelve month low of $289.21 and a twelve month high of $459.77. The business has a 50-day moving average of $335.25 and a two-hundred day moving average of $338.90. The company has a market capitalization of $9.28 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.